key: cord-0826331-b5vtpci8 authors: Arana, Carolt; Cuevas Ramírez, Rafael E.; Xipell, Marc; Casals, Joaquim; Moreno, Asunción; Herrera, Sabina; Bodro, Marta; Cofan, Frederic; Diekmann, Fritz; Esforzado, Núria title: Mucormycosis associated with COVID‐19 in two kidney transplant patients date: 2021-06-13 journal: Transpl Infect Dis DOI: 10.1111/tid.13652 sha: f247096cb8d6351d2a7cb29da2271412b2415ba2 doc_id: 826331 cord_uid: b5vtpci8 Coronavirus disease 2019 (COVID‐19) predisposes patients to bacterial and fungal superinfections due to the impairment of the immunological system. Among the associated opportunistic fungal infections, mucormycosis is one of the least frequent but with the highest mortality. We describe two cases of mucormycosis in two kidney transplant recipients, while they were hospitalized for SARS‐CoV‐2 pneumonia, with rhinosinusal and musculoskeletal involvement, respectively. Since the beginning of the coronavirus disease 2019 (COVID- 19) pandemic, there were alarming reports of secondary invasive fungal infections. 1 Although the incidence of fungal infection in COVID-19 patients is generally low, multiple cases have been reported globally, mainly pulmonary aspergillosis. Among the hypotheses raised to explain this connection, there is the pro-inflammatory state of the patient and the impairment of cellular immunity, in part due to the immunosuppressive regimens used in patients with severe Mucormycosis is an angioinvasive fungal infection associated with a high mortality, especially among immunosuppressed patients. 3 Diabetes mellitus is the main underlying disease associated with mucormycosis. Nevertheless, transplantation and hematological malignancies are also associated with this infection. A few case reports of COVID-19-associated mucormycosis have recently been published. Here, we present the first two cases of COVID-19 associated mucormycosis infection in kidney recipients. A 62-year-old man with past history of type 2 diabetes mellitus was treated with insulin with non-optimal control (last HbAc1 9.6%), and kidney transplantation 4 years prior, on immunosuppressive treatment with tacrolimus and prednisone with baseline creatinine of 1.4 mg/dL ( Table 1 ). The patient also had history of disseminated cryptococcosis in 2018 for which he was treated with fluconazole for the first 12 months followed by isavuconazole for an additional 12 months. Three months after finishing the antifungal treatment, he was admitted to the hospital for respiratory failure due to confirmed SARS-CoV-2 pneumonia (November 30, 2020). The patient presented severe respiratory failure and he was transferred to the intensive care unit (ICU) requiring non-invasive mechanical ventilation for 6 days and received treatment with intravenous (IV) dexamethasone 6 mg daily for 10 days and antibiotic empirical therapy with ceftriaxone 1 gr q24h + azithromycin 500 mg q24h. He had initial favorable clinical and radiological evolution. All bacterial cultures were negative. During admission, he did not present diabetic ketoacidosis. After an initial clinical improvement and after being discharged from the ICU, a week later, he presented fever, headache, and left malar region swelling. A facial computed tomography (CT) was The second case was a 48-year-old man with a history of chronic kidney disease due to reflux nephropathy. He received a fourth renal transplant from a cadaveric donor 5 years prior, and was on immunosuppressive treatment with prednisone, mycophenolate and tacrolimus (Table 1) . He had chronic graft dysfunction due to transplant glomerulopathy, with basal creatinine of 2.8 mg/dL. He was admitted to the hospital on April 14, 2020 with bilateral SARS-CoV-2 pneumonia. The patient was started on hydroxychloroquine, azithromycin and lopinavir/ritonavir and anticoagulation with prophylactic low weight heparin according to our hospital protocol at that time. Due to worsening respiratory failure, a unique dose of tocilizumab 400 mg was administered during the hospitalization. Tacrolimus and mycophenolate were stopped, and prednisone was maintained at a dose of 20 mg/d. During admission, he did not Mucormycosis is a rare invasive fungal infection, with an incidence of up to two of 1000 transplanted patients. 10 Rhinosinusal disease is the most common presentation of mucormycosis in solid organ transplant recipients, 3,10,17 and similar locations have been reported in COVID-19-associated cases. 9 However, pulmonary infection is also frequent. [18] [19] [20] [21] [22] [23] In these cases, the differential diagnosis with invasive pulmonary aspergillosis should be considered, since these two entities have similar risk factors and may present similar radiological patterns and clinical course. 24 The diagnosis of mucormycosis is made after isolating the pathogen in cultures obtained after surgery or bronchoalveolar lavage, tissue biopsy, or PCR-amplification. 3, 10 The lack of clinical suspicion and the difficulty in isolating the fungus could lead to a delay in diagnosis and treatment initiation. Currently, liposomal amphotericin B, posaconazole, isavuconazole, and itraconazole, although the latter with limited activity, are the main available therapeutic options. 25 Some studies have reported a lower mortality with the use of a combination of two antifungal compared to monotherapy. 26 More importantly one of the pillars of treatment is the surgical debridement of the necrotic tissue, which often has to be performed several times, as reflected in both of our cases. Hyperbaric chambers have been described as adjuvant therapy; although there are no randomized clinical trials, some case series data have shown a potential benefit. 27, 28 Transplant physicians must be aware that patients with COVID-19 are at risk of developing unusual opportunistic infections. Some authors suggest reducing immunosuppressant therapy in these patients, such as reducing or stopping CNI and antimetabolites (mycophenolate or azathioprine) in moderate or severe cases, leaving corticosteroids as monotherapy. However, in case of developing mucormycosis, different strategies other than steroids should be considered. [9] [10] [11] 29 The mortality of mucormycosis is high, with an estimate of around 30%-50%, 3,12 mostly attributed to impossibility to perform surgical debridement. In the published COVID-19 related cases, an even higher mortality rate was reported, up to even 90% of the patients, and in some, the diagnosis was made post-mortem. [18] [19] [20] [21] [22] [23] [30] [31] [32] [33] [34] However, lower rates have also been described in a recent review with an in-hospital mortality of 49% in a series of 41 cases. 35 Our cases had a more favorable outcome. This is explained in part due to the presentation, since the musculoskeletal forms are associated with a better prognosis, in part due to the accessibility to obtain histological samples allowing an early diagnosis. In both cases, the patients were able to benefit from surgical debridement. In conclusion, we believe these two cases reflect the importance of suspicion by transplant physicians of opportunistic infections in solid organ transplant recipients, particularly mucormycosis, in patients with severe COVID-19 infection, where patients have an impaired immune response and are commonly treated with high doses of corticosteroids. It is possible that this entity might be under diagnosed since these patients often have overlapping or non-specific symptoms, the complexity of the diagnosis, especially in cases with lung involvement. The authors declare that they have no conflicts of interest. CA and RC: data collection, data analysis and manuscript writing. MX and SH: conceptualization, data collection, data analysis, and manuscript editing. JC: data collection. AM, MB, FC, FD, and NE: conceptualization and manuscript editing. All authors approved the latest version of the manuscript. Data partially available on request due to privacy/ethical restrictions. COVID-19 associated pulmonary aspergillosis Fungal co-infection in COVID-19 patients: Should we be concerned? Mucormycosis in renal transplant recipients: review of 174 reported cases COVID-19 and kidney transplantation: results from the TANGO international transplant consortium A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients COVID-19 and renal transplantation Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Clinical and immunological features of severe and moderate coronavirus disease 2019 SARS-CoV-2, uncontrolled diabetes and corticosteroids-An unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature Disease entities in mucormycosis Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome Hsp90 orchestrates stress response signaling governing fungal drug resistance Calcineurin plays key roles in the dimorphic transition and virulence of the human pathogenic zygomycete Mucor circinelloides Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis A novel resistance pathway for calcineurin inhibitors in the human-pathogenic Mucorales Mucor circinelloides Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET) Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a postmortem study Coronavirus disease (Covid-19) Associated Mucormycosis (CAM): case report and systematic review of literature A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a Severe Acute Respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infect Dis Now Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically Ill COVID-19 Patient with Underlying Hematological Malignancy Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium Combination polyenecaspofungin treatment of rhino-orbital-cerebral mucormycosis Hyperbaric oxygen: applications in infectious disease Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients Mucormycosis with orbital compartment syndrome in a patient with COVID-19 Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 Patient: a case report acute invasive rhinoorbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome Rhino-orbital mucormycosis associated with COVID-19 A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19 When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis Mucormycosis associated with COVID-19 in two kidney transplant patients